For this study, outcomes were compared between 2 groups of patients with myasthenia gravis: those who developed exacerbations ...
Johnson & Johnson (NYSE: JNJ) has announced promising results from its pivotal Phase 3 Vivacity-MG3 study evaluating ...
The FDA has granted Priority Review to nipocalimab for the treatment of antibody positive patients with generalized myasthenia gravis.
Across 5 research centers, investigators evaluated the impact of eculizumab on thymoma-associated myasthenia gravis, a severe disease subtype.
The company also continues to study Descartes-08 in other autoimmune diseases and has plans for a basket trial in pediatric patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback